Pyxis Oncology, Inc. (PYXS)
After hours:
| Previous close | 4.3000 |
| Open | 4.2700 |
| Bid | 4.2800 x 200 |
| Ask | 4.3400 x 100 |
| Day's range | 4.2500 - 4.4199 |
| 52-week range | 1.3500 - 6.8500 |
| Volume | |
| Avg. volume | 795,060 |
| Market cap | 249.974M |
| Beta (5Y monthly) | 1.51 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8500 |
| Earnings date | 11 May 2024 - 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswirePyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired
- GlobeNewswire
Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rig
- GuruFocus.com
Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges
Financial Results for Q4 and Full Year 2023 Highlight Key Developments and Future Outlook
